Epilepsy in four genetically determined syndromes of intellectual disability

Journal of Intellectual Disability Research

Volumn 57, Issue 1, 2013, Pages 3-20

  Leung, H T T ^a   Ring, H ^b  

^a CHRIST S COLLEGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Epilepsy; Fragile X; Genetics; Intellectual disability; Rett; Tuberous sclerosis complex

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; CARBAMAZEPINE; ETIRACETAM; EVEROLIMUS; LAMOTRIGINE; RAPAMYCIN; VALPROIC ACID; VIGABATRIN;

ASTROCYTE; ATONIC SEIZURE; BRAIN DEVELOPMENT; CLINICAL FEATURE; DISEASE SEVERITY; ELECTROENCEPHALOGRAM; EPILEPSY; EPILEPTIC STATE; EPILEPTOGENESIS; EXCITABILITY; FOCAL EPILEPSY; FRAGILE X SYNDROME; GABAERGIC SYSTEM; GABAERGIC TRANSMISSION; GENE DELETION; GENE MUTATION; HAPPY PUPPET SYNDROME; HEMIZYGOSITY; HUMAN; INFANTILE SPASM; INTELLECTUAL IMPAIRMENT; INTRACTABLE EPILEPSY; LEARNING DISORDER; LONG TERM DEPRESSION; LONG TERM POTENTIATION; NEGATIVE FEEDBACK; NERVE CELL NETWORK; NERVE CELL PLASTICITY; NONHUMAN; PROTEIN SYNTHESIS; PSYCHOGENIC NONEPILEPTIC SEIZURE; RETT SYNDROME; REVIEW; SENSORY GATING; SOCIAL BEHAVIOR; SYNTHESIS; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TUBEROUS SCLEROSIS; UNIPARENTAL DISOMY; VAGUS NERVE STIMULATION;

ADOLESCENT; ANGELMAN SYNDROME; CHILD; CHILD, PRESCHOOL; EPILEPSY; FEMALE; FRAGILE X SYNDROME; HUMANS; INTELLECTUAL DISABILITY; MALE; RETT SYNDROME; TUBEROUS SCLEROSIS;

EID: 84870843714     PISSN: 09642633     EISSN: 13652788     Source Type: Journal    
DOI: 10.1111/j.1365-2788.2011.01505.x     Document Type: Review

References (149)

1. Adusei D. C., Pacey L. K. K., Chen D. & Hampson D. R. (2010) Early developmental alterations in GABAergic protein expression in fragile X knockout mice. Neuropharmacology 59, 167-71.
2. Aronica E., van Vliet E. A., Mayboroda O. A., Troost D., da Silva F. H. & Gorter J. A. (2000) Upregulation of metabotropic glutamate receptor subtype mGluR3 and mGluR5 in reactive astrocytes in a rat model of mesial temporal lobe epilepsy. The European Journal of Neuroscience 12, 2333-44.
3. Astrinidis A. & Henske E. P. (2005) Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene 24, 7475-81.
4. Bahi-Buisson N., Guellec I., Nabbout R., Guet A., Nguyen G., Dulac O. etal. (2008) Parental view of epilepsy in Rett syndrome. Brain & Development 30, 126-30.
5. Ballas N., Lioy D. T., Grunseich C. & Mandel G. (2009) Non-cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology. Nature Neuroscience 12, 311-17.
6. Barres B. A. (2008) The mystery and magic of glia: a perspective on their roles in health and disease. Neuron 60, 430-40.
7. Bear M. F., Huber K. M. & Warren S. T. (2004) The mGluR theory of fragile X mental retardation. Trends in Neurosciences 27, 370-7.
8. Benarroch E. E. (2009) Astrocyte-neuron interactions: implications for epilepsy. Neurology 73, 1323-7.
9. Berg A. T. (2011) Epilepsy, cognition, and behavior: the clinical picture. Epilepsia 52 (Suppl. 1), 7-12.
10. Berry-Kravis E. (2002) Epilepsy in fragile X syndrome. Developmental Medicine and Child Neurology 44, 724-8.
11. Berry-Kravis E., Sumis A., Hervey C., Nelson M., Porges S. W., Weng N. etal. (2008) Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. Journal of Developmental and Behavioral Pediatrics 29, 293-302.
12. Berry-Kravis E., Hessl D., Coffey S., Hervey C., Schneider A., Yuhas J. etal. (2009) A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. Journal of Medical Genetics 46, 266-71.
13. Berry-Kravis E., Raspa M., Loggin-Hester L., Bishop E., Holiday D. & Bailey D. B. (2010) Seizures in fragile X syndrome: characteristics and comorbid diagnoses. American Journal on Intellectual and Developmental Disabilities 115, 461-72.
14. Bianchi M. T., Haas K. F. & Macdonald R. L. (2002) Alpha1 and alpha6 subunits specify distinct desensitization, deactivation and neurosteroid modulation of GABA(A) receptors containing the delta subunit. Neuropharmacology 43, 492-502.
15. Bianchi R., Chuang S.-C., Zhao W., Young S. R., Wong R. K. S. (2009) Cellular plasticity for group I mGluR-mediated epileptogenesis. The Journal of Neuroscience 29, 3497-507.
16. Boer K., Troost D., Timmermans W., Gorter J. A., Spliet W. G. M., Nellist M. etal. (2008) Cellular localization of metabotropic glutamate receptors in cortical tubers and subependymal giant cell tumors of tuberous sclerosis complex. Neuroscience 156, 203-15.
17. Brooks-Kayal A. (2011) Molecular mechanisms of cognitive and behavioral comorbidities of epilepsy in children. Epilepsia 52 (Suppl. 1), 13-20.
18. Brouwer J. R., Willemsen R. & Oostra B. A. (2009) The FMR1 gene and fragile X-associated tremor/ataxia syndrome. American Journal of Medical Genetics. Part B 150B, 782-98.
19. Burbea M., Dreier L., Dittman J. S., Grunwald M. E. & Kaplan J. M. (2002) Ubiquitin and AP180 regulate the abundance of GLR-1 glutamate receptors at postsynaptic elements in C. elegans. Neuron 35, 107-20.
20. Bushong E. A., Martone M. E., Jones Y. Z. & Ellisman M. H. (2002) Protoplasmic astrocytes in CA1 stratum radiatum occupy separate anatomical domains. The Journal of Neuroscience 22, 183-92.
21. Cardoza B., Clarke A., Wilcox J., Gibbon F., Smith P. E., Archer H. etal. (2011) Epilepsy in Rett syndrome association between phenotype and genotype, and implications for practice. Seizure 20, 646-9.
22. Chahrour M., Jung S. Y., Shaw C., Zhou X., Wong S. T. C., Qin J. etal. (2008) MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 320, 1224-9.
23. Chao H.-T., Zoghbi H. Y. & Rosenmund C. (2007) MeCP2 controls excitatory synaptic strength by regulating glutamatergic synapse number. Neuron 56, 58-65.
24. Chao H.-T., Chen H., Samaco R. C., Xue M., Chahrour M., Yoo J. etal. (2010) Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature 468, 263-9.
25. Chapman M., Iddon P., Atkinson K., Brodie C., Mitchell D., Parvin G. etal. (2011) The misdiagnosis of epilepsy in people with intellectual disabilities: a systematic review. Seizure 20, 101-6.
26. Chen W. G., Chang Q., Lin Y., Meissner A., West A. E., Griffith E. C. etal. (2003) Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science 302, 885-9.
27. Chuang S.-C., Zhao W., Bauchwitz R., Yan Q., Bianchi R. & Wong R. K. S. (2005) Prolonged epileptiform discharges induced by altered group I metabotropic glutamate receptor-mediated synaptic responses in hippocampal slices of a fragile X mouse model. The Journal of Neuroscience 25, 8048-55.
28. Chu-Shore C. J., Major P., Camposano S., Muzykewicz D. & Thiele E. A. (2010) The natural history of epilepsy in tuberous sclerosis complex. Epilepsia 51, 1236-41.
29. Colgin L. L., Kubota D., Jia Y., Rex C. S. & Lynch G. (2004) Long-term potentiation is impaired in rat hippocampal slices that produce spontaneous sharp waves. The Journal of Physiology 558, 953-61.
30. Curatolo P. (2010) Intractable epilepsy in tuberous sclerosis: is the tuber removal not enough? Developmental Medicine and Child Neurology 52, 987.
31. Curia G., Papouin T., Séguéla P. & Avoli M. (2009) Downregulation of tonic GABAergic inhibition in a mouse model of fragile X syndrome. Cerebral Cortex 19, 1515-20.
32. D'Hulst C. & Kooy R. F. (2007) The GABAA receptor: a novel target for treatment of fragile X? Trends in Neurosciences 30, 425-31.
33. D'Hulst C., De Geest N., Reeve S. P., Van Dam D., De Deyn P. P., Hassan B. A. etal. (2006) Decreased expression of the GABAA receptor in fragile X syndrome. Brain Research 1121, 238-45.
34. D'Hulst C., Heulens I., Brouwer J. R., Willemsen R., De Geest N., Reeve S. P. etal. (2009) Expression of the GABAergic system in animal models for fragile X syndrome and fragile X associated tremor/ataxia syndrome (FXTAS). Brain Research 1253, 176-83.
35. Dan B. (2009) Angelman syndrome: current understanding and research prospects. Epilepsia 50, 2331-9.
36. Dan B. & Boyd S. G. (2003) Angelman syndrome reviewed from a neurophysiological perspective. The UBE3A-GABRB3 hypothesis. Neuropediatrics 34, 169-76.
37. Dan B., Boyd S. G., Pelc K. & Cheron G. (2007) Lamotrigine effect on GABA transmission in Angelman syndrome? Epilepsia 48, 1634.
38. Dani V. S. & Nelson S. B. (2009) Intact long-term potentiation but reduced connectivity between neocortical layer 5 pyramidal neurons in a mouse model of Rett syndrome. The Journal of Neuroscience 29, 11263-70.
39. Dani V. S., Chang Q., Maffei A., Turrigiano G. G., Jaenisch R. & Nelson S. B. (2005) Reduced cortical activity due to a shift in the balance between excitation and inhibition in a mouse model of Rett syndrome. Proceedings of the National Academy of Sciences of the United States of America 102, 12560-5.
40. DeLorey T. M., Handforth A., Anagnostaras S. G., Homanics G. E., Minassian B. A., Asatourian A. etal. (1998) Mice lacking the beta3 subunit of the GABAA receptor have the epilepsy phenotype and many of the behavioral characteristics of Angelman syndrome. The Journal of Neuroscience 18, 8505-14.
41. Dion M. H., Novotny E. J. Jr, Carmant L., Cossette P. & Nguyen D. K. (2007) Lamotrigine therapy of epilepsy with Angelman's syndrome. Epilepsia 48, 593-6.
42. Dockendorff T. C., Su H. S., McBride S. M. J., Yang Z., Choi C. H., Siwicki K. K. etal. (2002) Drosophila lacking dfmr1 activity show defects in circadian output and fail to maintain courtship interest. Neuron 34, 973-84.
43. Doherty C., Goh S., Young Poussaint T., Erdag N. & Thiele E. A. (2005) Prognostic significance of tuber count and location in tuberous sclerosis complex. Journal of Child Neurology 20, 837-41.
44. Dölen G., Osterweil E., Rao B. S. S., Smith G. B., Auerbach B. D., Chattarji S. etal. (2007) Correction of fragile X syndrome in mice. Neuron 56, 955-62.
45. Egawa K., Asahina N., Shiraishi H., Kamada K., Takeuchi F., Nakane S. etal. (2008) Aberrant somatosensory-evoked responses imply GABAergic dysfunction in Angelman syndrome. Neuroimage 39, 593-9.
46. Ehninger D. & Silva A. J. (2011) Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders. Trends in Molecular Medicine 17, 78-87.
47. Ehninger D., Han S., Shilyansky C., Zhou Y., Li W., Kwiatkowski D. J. etal. (2008) Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nature Medicine 14, 843-8.
48. Ehninger D., de Vries P. J. & Silva A. J. (2009) From mTOR to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis. Journal of Intellectual Disability Research 53, 838-51.
49. El Idrissi A., Ding X.-H., Scalia J., Trenkner E., Brown W. T. & Dobkin C. (2005) Decreased GABA(A) receptor expression in the seizure-prone fragile X mouse. Neuroscience Letters 377, 141-6.
50. Fellin T., Pascual O., Gobbo S., Pozzan T., Haydon P. G. & Carmignoto G. (2004) Neuronal synchrony mediated by astrocytic glutamate through activation of extrasynaptic NMDA receptors. Neuron 43, 729-43.
51. Forsgren L., Hauser W. A., Olafsson E., Sander J. W., Sillanpää M. & Tomson T. (2005) Mortality of epilepsy in developed countries: a review. Epilepsia 46 (Suppl. 11), 18-27.
52. Gantois I., Vandesompele J., Speleman F., Reyniers E., D'Hooge R., Severijnen L.-A. etal. (2006) Expression profiling suggests underexpression of the GABA(A) receptor subunit delta in the fragile X knockout mouse model. Neurobiology of Disease 21, 346-57.
53. Gauthey M., Poloni C. B., Ramelli G. P., Roulet-Perez E. & Korff C. M. (2010) Status epilepticus in fragile X syndrome. Epilepsia 51, 2470-3.
54. Gibson J. R., Bartley A. F., Hays S. A. & Huber K. M. (2008) Imbalance of neocortical excitation and inhibition and altered UP states reflect network hyperexcitability in the mouse model of fragile X syndrome. Journal of Neurophysiology 100, 2615-26.
55. Glaze D. G., Percy A. K., Skinner S., Motil K. J., Neul J. L., Barrish J. O. etal. (2010) Epilepsy and the natural history of Rett syndrome. Neurology 74, 909-12.
56. Gómez-Gonzalo M., Losi G., Chiavegato A., Zonta M., Cammarota M., Brondi M. etal. (2010) An excitatory loop with astrocytes contributes to drive neurons to seizure threshold. PLoS Biology 8, e1000352.
57. Goorden S. M., van Woerden G. M., van der Weerd L., Cheadle J. P. & Elgersma Y. (2007) Cognitive deficits in Tsc1+/- mice in the absence of cerebral lesions and seizures. Annals of Neurology 62, 648-55.
58. Gross C., Yao X., Pong D. L., Jeromin A. & Bassell G. J. (2011) Fragile x mental retardation protein regulates protein expression and mRNA translation of the potassium channel Kv4.2. The Journal of Neuroscience 31, 5693-8.
59. Hagerman P. J. & Stafstrom C. E. (2009) Origins of epilepsy in fragile X syndrome. Epilepsy Currents 9, 108-12.
60. Heulens I., D'Hulst C., Braat S., Rooms L. & Kooy R. F. (2010) Involvement and therapeutic potential of the GABAergic system in the fragile X syndrome. Thescientificworldjournal 10, 2198-206.
61. Hogart A., Nagarajan R. P., Patzel K. A., Yasui D. H. & Lasalle J. M. (2007) 15q11-13 GABAA receptor genes are normally biallelically expressed in brain yet are subject to epigenetic dysregulation in autism-spectrum disorders. Human Molecular Genetics 16, 691-703.
62. Holmes G. L. & Stafstrom C. E. (2007) Tuberous sclerosis complex and epilepsy: recent developments and future challenges. Epilepsia 48, 617-30.
63. Holopainen I. E., Metsähonkala E. L., Kokkonen H., Parkkola R. K., Manner T. E., Någren K. etal. (2001) Decreased binding of [11C]flumazenil in Angelman syndrome patients with GABA(A) receptor beta3 subunit deletions. Annals of Neurology 49, 110-13.
64. Homanics G. E., DeLorey T. M., Firestone L. L., Quinlan J. J., Handforth A., Harrison N. L. etal. (1997) Mice devoid of gamma-aminobutyrate type A receptor beta3 subunit have epilepsy, cleft palate, and hypersensitive behavior. Proceedings of the National Academy of Sciences of the United States of America 94, 4143-8.
65. Irwin S. A., Galvez R. & Greenough W. T. (2000) Dendritic spine structural anomalies in fragile-X mental retardation syndrome. Cerebral Cortex 10, 1038-44.
66. Jacobs S. & Doering L. C. (2010) Astrocytes prevent abnormal neuronal development in the fragile x mouse. The Journal of Neuroscience 30, 4508-14.
67. Jacobs S., Nathwani M. & Doering L. C. (2010) Fragile X astrocytes induce developmental delays in dendrite maturation and synaptic protein expression. BMC Neuroscience 11, 132.
68. Jambaqué I., Cusmai R., Curatolo P., Cortesi F., Perrot C. & Dulac O. (1991) Neuropsychological aspects of tuberous sclerosis in relation to epilepsy and MRI findings. Developmental Medicine and Child Neurology 33, 698-705.
69. Jansen F. E., van Huffelen A. C., Algra A. & van Nieuwenhuizen O. (2007) Epilepsy surgery in tuberous sclerosis: a systematic review. Epilepsia 48, 1477-84.
70. Jansen L. A., Uhlmann E. J., Crino P. B., Gutmann D. H. & Wong M. (2005) Epileptogenesis and reduced inward rectifier potassium current in tuberous sclerosis complex-1-deficient astrocytes. Epilepsia 46, 1871-80.
71. Jay V., Becker L. E., Chan F. W. & Perry T. L. Sr (1991) Puppet-like syndrome of Angelman: a pathologic and neurochemical study. Neurology 41, 416-22.
72. Jefferys J. G. R. (2010) Advances in understanding basic mechanisms of epilepsy and seizures. Seizure 19, 638-46.
73. Jian L., Nagarajan L., de Klerk N., Ravine D., Christodolou J. & Leonard H. (2007) Seizures in Rett syndrome: an overview from a one-year calendar study. European Journal of Paediatric Neurology 11, 310-17.
74. Kanner A. M. (2011) Depression and epilepsy: a bidirectional relation? Epilepsia 52 (Suppl. 1), 21-7.
75. Kassiri J., Snyder T. J., Bhargava B., Wheatley M. & Sinclair D. B. (2011) Cortical tubers, cognition, and epilepsy in tuberous sclerosis. Pediatric Neurology 44, 328-32.
76. Kaufmann W. E. & Moser H. W. (2000) Dendritic anomalies in disorders associated with mental retardation. Cerebral Cortex 10, 981-91.
77. Krajnc N., Zupancic N. & Orazem J. (2011) Epilepsy treatment in Rett syndrome. Journal of Child Neurology DOI: 10.1177/0883073811408422 [published online ahead of print 2 June].
78. Krasowski M. D., Rick C. E., Harrison N. L., Firestone L. L. & Homanics G. E. (1998) A deficit of functional GABA(A) receptors in neurons of beta 3 subunit knockout mice. Neuroscience Letters 240, 81-4.
79. Krueger D. A., Care M. M., Holland K., Agricola K., Tudor A., Mangeshkar P. etal. (2010) Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. The New England Journal of Medicine 363, 1801-11.
80. Lalande M. & Calciano M. A. (2007) Molecular epigenetics of Angelman syndrome. Cellular and Molecular Life Sciences 64, 947-60.
81. Laurie D. J., Wisden W. & Seeburg P. H. (1992) The distribution of thirteen GABAA receptor subunit mRNAs in the rat brain. III. Embryonic and postnatal development. The Journal of Neuroscience 12, 4151-72.
82. Lhatoo S. D. & Sander J. W. (2001) The epidemiology of epilepsy and learning disability. Epilepsia 42 (Suppl. 1), 6-9.
83. Lossie A. C., Whitney M. M., Amidon D., Dong H. J., Chen P., Theriaque D. etal. (2001) Distinct phenotypes distinguish the molecular classes of Angelman syndrome. Journal of Medical Genetics 38, 834-45.
84. Mackay M. T., Weiss S. K., Adams-Webber T., Ashwal S., Stephens D., Ballaban-Gill K. etal. (2004) Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. Neurology 62, 1668-81.
85. Maezawa I. & Jin L.-W. (2010) Rett syndrome microglia damage dendrites and synapses by the elevated release of glutamate. The Journal of Neuroscience 30, 5346-56.
86. Maezawa I., Swanberg S., Harvey D., LaSalle J. M. & Jin L.-W. (2009) Rett syndrome astrocytes are abnormal and spread MeCP2 deficiency through gap junctions. The Journal of Neuroscience 29, 5051-61.
87. Malmgren K., Olsson I., Engman E., Flink R. & Rydenhag B. (2008) Seizure outcome after resective epilepsy surgery in patients with low IQ. Brain 131, 535-42.
88. Marchetto M. C., Carromeu C., Acab A., Yu D., Yeo G. W., Mu Y. etal. (2010) A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 143, 527-39.
89. Mauch D. H., Nägler K., Schumacher S., Göritz C., Müller E. C., Otto A. etal. (2001) CNS synaptogenesis promoted by glia-derived cholesterol. Science 294, 1354-7.
90. McGrother C. W., Bhaumik S., Thorp C. F., Hauck A., Branford D. & Watson J. M. (2006) Epilepsy in adults with intellectual disabilities: prevalence, associations and service implications. Seizure 15, 376-86.
91. Medrihan L., Tantalaki E., Aramuni G., Sargsyan V., Dudanova I., Missler M. etal. (2008) Early defects of GABAergic synapses in the brain stem of a MeCP2 mouse model of Rett syndrome. Journal of Neurophysiology 99, 112-21.
92. Meikle L., Pollizzi K., Egnor A., Kramvis I., Lane H., Sahin M. etal. (2008) Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. The Journal of Neuroscience 28, 5422-32.
93. Minassian B. A., DeLorey T. M., Olsen R. W., Philippart M., Bronstein Y., Zhang Q. etal. (1998) Angelman syndrome: correlations between epilepsy phenotypes and genotypes. Annals of Neurology 43, 485-93.
94. Moavero R., Cerminara C. & Curatolo P. (2010) Epilepsy secondary to tuberous sclerosis: lessons learned and current challenges. Child's Nervous System 26, 1495-504.
95. Muncy J., Butler I. J. & Koenig M. K. (2009) Rapamycin reduces seizure frequency in tuberous sclerosis complex. Journal of Child Neurology 24, 477.
96. Musumeci S. A., Hagerman R. J., Ferri R., Bosco P., Dalla Bernardina B., Tassinari C. A. etal. (1999) Epilepsy and EEG findings in males with fragile X syndrome. Epilepsia 40, 1092-9.
97. Nicholls R. D. (1998) Strange bedfellows? Protein degradation and neurological dysfunction. Neuron 21, 647-9.
98. Nissenkorn A., Gak E., Vecsler M., Reznik H., Menascu S. & Ben Zeev B. (2010) Epilepsy in Rett syndrome - the experience of a National Rett Center. Epilepsia 51, 1252-8.
99. O'Callaghan F. J. K., Harris T., Joinson C., Bolton P., Noakes M., Presdee D. etal. (2004) The relation of infantile spasms, tubers, and intelligence in tuberous sclerosis complex. Archives of Disease in Childhood 89, 530-3.
100. Odano I., Anezaki T., Ohkubo M., Yonekura Y., Onishi Y., Inuzuka T. etal. (1996) Decrease in benzodiazepine receptor binding in a patient with Angelman syndrome detected by iodine-123 iomazenil and single-photon emission tomography. European Journal of Nuclear Medicine 23, 598-604.
101. Olmos-Serrano J. L., Paluszkiewicz S. M., Martin B. S., Kaufmann W. E., Corbin J. G. & Huntsman M. M. (2010) Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome. The Journal of Neuroscience 30, 9929-38.
102. Orlova K. A. & Crino P. B. (2010) The tuberous sclerosis complex. Annals of the New York Academy of Sciences 1184, 87-105.
103. Pacey L. K. K. & Doering L. C. (2007) Developmental expression of FMRP in the astrocyte lineage: implications for fragile X syndrome. Glia 55, 1601-9.
104. Pelc K., Boyd S. G., Cheron G. & Dan B. (2008) Epilepsy in Angelman syndrome. Seizure 17, 211-17.
105. Pesaturo K. A., Spooner L. M. & Belliveau P. (2011) Vigabatrin for infantile spasms. Pharmacotherapy 31, 298-311.
106. Pfeiffer B. E. & Huber K. M. (2009) The state of synapses in fragile X syndrome. The Neuroscientist 15, 549-67.
107. Pfrieger F. W. & Barres B. A. (1997) Synaptic efficacy enhanced by glial cells in vitro. Science 277, 1684-7.
108. Pintaudi M., Calevo M. G., Vignoli A., Parodi E., Aiello F., Baglietto M. G. etal. (2010) Epilepsy in Rett syndrome: clinical and genetic features. Epilepsy & Behavior 19, 296-300.
109. Pitkänen A. & Lukasiuk K. (2011) Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurology 10, 173-86.
110. Powell E. M. & Geller H. M. (1999) Dissection of astrocyte-mediated cues in neuronal guidance and process extension. Glia 26, 73-83.
111. Qiu L.-F., Hao Y.-H., Li Q.-Z. & Xiong Z.-Q. (2008) Fragile X syndrome and epilepsy. Neuroscience Bulletin 24, 338-44.
112. Qiu L.-F., Lu T.-J., Hu X.-L., Yi Y.-H., Liao W.-P. & Xiong Z.-Q. (2009) Limbic epileptogenesis in a mouse model of fragile X syndrome. Cerebral Cortex 19, 1504-14.
113. Ridler K., Suckling J., Higgins N., Bolton P. & Bullmore E. (2004) Standardized whole brain mapping of tubers and subependymal nodules in tuberous sclerosis complex. Journal of Child Neurology 19, 658-65.
114. Roden W. H., Peugh L. D. & Jansen L. A. (2010) Altered GABA(A) receptor subunit expression and pharmacology in human Angelman syndrome cortex. Neuroscience Letters 483, 167-72.
115. Ruggieri M. & McShane M. A. (1998) Parental view of epilepsy in Angelman syndrome: a questionnaire study. Archives of Disease in Childhood 79, 423-6.
116. Saitoh S., Harada N., Jinno Y., Hashimoto K., Imaizumi K., Kuroki Y. etal. (1994) Molecular and clinical study of 61 Angelman syndrome patients. American Journal of Medical Genetics 52, 158-63.
117. Samaco R. C., Hogart A. & LaSalle J. M. (2005) Epigenetic overlap in autism-spectrum neurodevelopmental disorders: MECP2 deficiency causes reduced expression of UBE3A and GABRB3. Human Molecular Genetics 14, 483-92.
118. Selby L., Zhang C. & Sun Q.-Q. (2007) Major defects in neocortical GABAergic inhibitory circuits in mice lacking the fragile X mental retardation protein. Neuroscience Letters 412, 227-32.
119. Shepherd J. D. & Bear M. F. (2011) New views of Arc, a master regulator of synaptic plasticity. Nature Neuroscience 14, 279-84.
120. Sinkkonen S. T., Homanics G. E. & Korpi E. R. (2003) Mouse models of Angelman syndrome, a neurodevelopmental disorder, display different brain regional GABA(A) receptor alterations. Neuroscience Letters 340, 205-8.
121. Sosunov A. A., Wu X., Weiner H. L., Mikell C. B., Goodman R. R., Crino P. D. etal. (2008) Tuberous sclerosis: a primary pathology of astrocytes? Epilepsia 49 (Suppl. 2), 53-62.
122. Sparagana S. P., Delgado M. R., Batchelor L. L. & Roach E. S. (2003) Seizure remission and antiepileptic drug discontinuation in children with tuberous sclerosis complex. Archives of Neurology 60, 1286-9.
123. Specchio N., Balestri M., Striano P., Cillo M. R., Nardello R., Patanè S. etal. (2010) Efficacy of levetiracetam in the treatment of drug-resistant Rett syndrome. Epilepsy Research 88, 112-17.
124. Stafstrom C. E. (2006) Epilepsy: a review of selected clinical syndromes and advances in basic science. Journal of Cerebral Blood Flow and Metabolism 26, 983-1004.
125. Stafstrom C. E. & Tempel B. L. (2000) Epilepsy genes: the link between molecular dysfunction and pathophysiology. Mental Retardation and Developmental Disabilities Research Reviews 6, 281-92.
126. Staley B. A., Vail E. A. & Thiele E. A. (2011) Tuberous sclerosis complex: diagnostic challenges, presenting symptoms, and commonly missed signs. Pediatrics 127, e117-25.
127. Steffenburg U., Hagberg G. & Hagberg B. (2001) Epilepsy in a representative series of Rett syndrome. Acta Paediatrica 90, 34-9.
128. Takano T., Tian G.-F., Peng W., Lou N., Libionka W., Han X. etal. (2006) Astrocyte-mediated control of cerebral blood flow. Nature Neuroscience 9, 260-7.
129. Talos D. M., Black P. M. & Jensen F. E. (2003) Dysplastic neurons in cortical tubers express selective alterations in AMPA and NMDA receptor subunits. Epilepsia 44 (Suppl. 8), 36.
130. Talos D. M., Kwiatkowski D. J., Cordero K., Black P. M. & Jensen F. E. (2008) Cell-specific alterations of glutamate receptor expression in tuberous sclerosis complex cortical tubers. Annals of Neurology 63, 454-65.
131. Tanaka K., Watase K., Manabe T., Yamada K., Watanabe M., Takahashi K. etal. (1997) Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 276, 1699-702.
132. Thibert R. L., Conant K. D., Braun E. K., Bruno P., Said R. R., Nespeca M. P. etal. (2009) Epilepsy in Angelman syndrome: a questionnaire-based assessment of the natural history and current treatment options. Epilepsia 50, 2369-76.
133. Tian G.-F., Azmi H., Takano T., Xu Q., Peng W., Lin J. etal. (2005) An astrocytic basis of epilepsy. Nature Medicine 11, 973-81.
134. Turky A., Felce D., Jones G. & Kerr M. (2011) A prospective case control study of psychiatric disorders in adults with epilepsy and intellectual disability. Epilepsia 52, 1223-30.
135. Uhlmann E. J., Wong M., Baldwin R. L., Bajenaru M. L., Onda H., Kwiatkowski D. J. etal. (2002) Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures. Annals of Neurology 52, 285-96.
136. Ullian E. M., Sapperstein S. K., Christopherson K. S. & Barres B. A. (2001) Control of synapse number by glia. Science 291, 657-61.
137. de Vries P. J. (2010) Targeted treatments for cognitive and neurodevelopmental disorders in tuberous sclerosis complex. Neurotherapeutics 7, 275-82.
138. de Vries P. J. & Howe C. J. (2007) The tuberous sclerosis complex proteins - a GRIPP on cognition and neurodevelopment. Trends in Molecular Medicine 13, 319-26.
139. Waltereit R., Japs B., Schneider M., de Vries P. J. & Bartsch D. (2011) Epilepsy and Tsc2 haploinsufficiency lead to autistic-like social deficit behaviors in rats. Behavior Genetics 41, 364-72.
140. Wetherington J., Serrano G. & Dingledine R. (2008) Astrocytes in the epileptic brain. Neuron 58, 168-78.
141. White R., Hua Y., Scheithauer B., Lynch D. R., Henske E. P. & Crino P. B. (2001) Selective alterations in glutamate and GABA receptor subunit mRNA expression in dysplastic neurons and giant cells of cortical tubers. Annals of Neurology 49, 67-78.
142. Winden K. D., Karsten S. L., Bragin A., Kudo L. C., Gehman L., Ruidera J. etal. (2011) A systems level, functional genomics analysis of chronic epilepsy. PLoS ONE 6, e20763.
143. Winterkorn E. B., Pulsifer M. B. & Thiele E. A. (2007) Cognitive prognosis of patients with tuberous sclerosis complex. Neurology 68, 62-4.
144. Wong M., Ess K. C., Uhlmann E. J., Jansen L. A., Li W., Crino P. B. etal. (2003) Impaired glial glutamate transport in a mouse tuberous sclerosis epilepsy model. Annals of Neurology 54, 251-6.
145. Yuskaitis C. J., Beurel E. & Jope R. S. (2010a) Evidence of reactive astrocytes but not peripheral immune system activation in a mouse model of Fragile X syndrome. Biochimica et Biophysica Acta 1802, 1006-12.
146. Yuskaitis C. J., Mines M. A., King M. K., Sweatt J. D., Miller C. A. & Jope R. S. (2010b) Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome. Biochemical Pharmacology 79, 632-46.
147. Zeng L.-H., Xu L., Gutmann D. H. & Wong M. (2008) Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Annals of Neurology 63, 444-53.
148. Zeng L.-H., Bero A. W., Zhang B., Holtzman D. M. & Wong M. (2010) Modulation of astrocyte glutamate transporters decreases seizures in a mouse model of Tuberous Sclerosis Complex. Neurobiology of Disease 37, 764-71.
149. Zhang L., He J., Jugloff D. G. M. & Eubanks J. H. (2008) The MeCP2-null mouse hippocampus displays altered basal inhibitory rhythms and is prone to hyperexcitability. Hippocampus 18, 294-309.